Long-Term Clinical Outcomes and Sequelae of Therapy in Early-Stage Orbital Mucosa-Associated Lymphoid Tissue Lymphoma

We report the clinical outcomes in early-stage primary orbital mucosa-associated lymphoid tissue (MALT) lymphoma. Retrospective analysis of adult patients treated from 1999 to 2017 at our institute was carried out 8-year OS, RFS and LC rates were 96.5%,88.5%, 96.7% respectively and cataract was the most common sequelae. Radiotherapy results in excellent clinical outcomes in early-stage orbital MALT lymphoma. Introduction: Orbital mucosa-associated lymphoid tissue (MALT) lymphoma, which are rare and indolent, often present at an early stage. We report the efficacy and safety outcomes of treatment in these patients. Methods: We analyzed adult patients with stage IE or IIE orbital MALT lymphoma between 1999 and 2017 treated at our institute. We assessed local control (LC) rates, overall survival (OS), relapse-free survival (RFS) using Kaplan Meier method and the incidence of late toxicities. Results: Seventy patients were analyzed for clinical outcomes. The median age at diagnosis was 52 years (IQR-45-62 years). Radiotherapy was offered to 97% of patients and the dose ranged from 36 to 45 Gy. Chemotherapy was administered in 5(7.1%) patients. Relapse occurred in 8 patients (local: 2, distant: 6). At a median follow-up of 101 months (IQR-47-146 months), the median OS and RFS was not reached. 8-year OS, RFS and LC rates were 96.5%, 88.5%, 96.7% respectively. Univariate analysis showed age <= 60 years and lacrimal involvement significantly correlated with better OS ( P = .01 and .04, respectively). Cataract was the most common sequelae observed in 31 patients (44.3%). Conclusion: Moderate doses of radiotherapy are curative in early-stage orbital MALT lymphoma with favorable clinical outcomes. Lower doses of radiation can reduce the toxicity further, without compromising efficacy. (C) 2021 Elsevier Inc. All rights reserved.